SCHEMBL17154374

SCHEMBL17154374

CC(=O)Nc1cccc(Nc2c3ccccc3nc3ccccc23)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.76
KDM4E B2RXH2 5/20 0.76
MAPT P10636 4/20 0.76
POLB P06746 3/20 0.76
KDM1A O60341 3/20 0.76
SMN1; SMN2 Q16637 3/20 0.76
L3MBTL1 Q9Y468 2/20 0.76
RAD52 P43351 2/20 0.76
MITF O75030 1/20 0.76
LMNA P02545 1/20 0.76
RECQL P46063 1/20 0.76
NPSR1 Q6W5P4 1/20 0.76
ABCG2 Q9UNQ0 4/20 0.67
ABCB1 P08183 2/20 0.67
ABCC1 P33527 1/20 0.67
MEN1 O00255 5/20 0.65
MAPK1 P28482 1/20 0.65
TOP2A P11388 2/20 0.65
GFER P55789 1/20 0.62
HDAC4 P56524 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17154400 0.87 KDM1A (1.00) KMT2AKDM4EMAPTPOLBKDM1A
SCHEMBL9300852 0.86 KMT2A (0.72) KMT2AKDM4EMAPTPOLBKDM1A
SCHEMBL9300052 0.83 TOP2A (0.73) KMT2AKDM4EMAPTPOLBKDM1A
SCHEMBL17154362 0.82 KDM1A (0.74) KMT2AKDM4EMAPTPOLBKDM1A
SCHEMBL29117960 0.80 KMT2A (0.65) KMT2AKDM4EMAPTPOLBKDM1A
SCHEMBL9300054 0.80 TOP2A (0.74) KMT2AKDM4EMAPTPOLBKDM1A
SCHEMBL1934668 0.80 MAPT (0.75) KMT2AMAPTPOLBL3MBTL1LMNA
SCHEMBL31436022 0.80 MAPT (0.75) KMT2AMAPTPOLBL3MBTL1LMNA
SCHEMBL3074031 0.80 KDM4E (0.71) KMT2AKDM4EMAPTPOLBKDM1A
SCHEMBL14116117 0.79 KMT2A (0.97) KMT2AKDM4EMAPTPOLBKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10183912-B2 HDMX inhibitors and their use for cancer treatment MiRx Pharmaceuticals, LLC (US) 2019-01-22 US disclosed
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MIRX PHARMACEUTICALS LLC (US) 2017-01-26 US disclosed
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MIRX PHARMACEUTICALS LLC (US) 2017-01-26 US disclosed
WO-2015153535-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MiRx Pharmaceuticals, LLC (US) 2015-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT TP53, DDX3X, API5 KMT2A 1544/4885KDM4E 809/4885MAPT 2621/4885
US-10183912-B2 HDMX inhibitors and their use for cancer treatment TP53, MDM4, MDM2 KMT2A 1514/4885KDM4E 839/4885MAPT 2632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.